Bajaj Healthcare

Quick check

The five things to look at first. Open one for more.

• DebtAdequate safetyRated A by India Ratings.
• ResultsGrowingIn the Sep 2026 quarter, sales rose 19% and profit rose 27% from a year earlier.
• DilutionNo new sharesNo new shares issued in the last year, so existing shareholders' slices were not cut.
• PromotersPromoters sellingThe promoters (founders or parent) own 59%, down from 59% in Sep 2025.
• ValuationNormal for this stockThe share trades at 18.1 times its yearly earnings (P/E), cheaper than 64% of the time in the last 5 years. Its usual P/E is about 20.

Bajaj Healthcare against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)18.1 against a typical 34.3: cheaper than most peers (1st = cheapest).48th of 220
• Sales growth+18.9% against a typical +15.6% from a year earlier.86th of 197
• Profit growth+27.3% against a typical +18.9% from a year earlier.73rd of 160
• Share price, 3 months−4.3% against a typical 0%.117th of 200
• Size₹ 1,055.1 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).86th of 199

Exchange filings and their impact on the company.

• 27 Oct 2026Analysts/Institutional Investor Meet/Con. Call UpdatesMedium impactPositivePrice +1.2% on 28 Oct
  Strong Q2 with 19% revenue and 27% PAT growth, on track for 10-15% FY27 growth at 18%+ margins toward Rs 900-1000 cr by FY29.

  Bajaj Healthcare reported a strong Q2 FY27 with revenue up 18.9% to Rs 175.9 cr and PAT up 26.9% to Rs 14.1 cr, with H1 revenue up 15.1% to Rs 341.5 cr at 18.1% EBITDA margin. Management said it is on track for 10-15% FY27 growth at 18-20% margins, launched Cenobamate tablets in September via 8 partners, got NCLT approval for Genrx, and was upgraded by India Ratings to IND A Stable. It is building a 250 kg peptide plant by March 2027, an oncology API plant by Q2 FY28 and a Nashik formulation plant, targeting Rs 900-1000 cr revenue by FY29 at 18-21% EBITDA margin.

  Full analysisFiling
• 17 Oct 2026Outcome of Board MeetingMedium impactPositivePrice −0.8% on 19 Oct
  Strong Q2/H1 with 15-19% sales growth and sharply higher profits signals faster earnings recovery.

  Bajaj Healthcare reported unaudited Q2 FY27 revenue of Rs 175.9 crore, up about 19% from last year, and H1 revenue of Rs 341.5 crore, up about 15%. Continuing profit after tax was Rs 14.4 crore in Q2 and Rs 28.3 crore in H1, with total H1 profit of Rs 27.8 crore as losses from discontinued Tarapur and Dahej units narrowed. The growth came with heavy investment: Rs 61 crore capex in H1, higher inventories and receivables, and a rise in borrowings, partly offset by sale of part of the Dahej land.

  Full analysisFiling
• 14 Oct 2026General UpdatesLow impactPositivePrice +2.3% on 15 Oct
  NCLT approved Bajaj Healthcare's going-concern purchase of liquidated Genrx Pharma; size undisclosed, likely small capacity add.

  Bajaj Healthcare received NCLT Mumbai order dated October 13, 2026 approving its acquisition of Genrx Pharmaceuticals, which was in liquidation, on a going-concern basis. The filing follows earlier disclosures in April 2025 but gives no purchase price or financial details. The deal adds a distressed pharma asset that should aid capacity over time, with only a small near-term impact pending completion details.

  Full analysisFiling
• 12 Oct 2026General UpdatesLow impactPositivePrice −0.6% on 13 Oct
  Sold Dahej undertaking for undisclosed sum, giving small one-time cash and profit boost.

  Bajaj Healthcare has executed a deed to sell its undertaking at Plot D-2/CH/42 & 43, Dahej Industrial Area, Gujarat to Spa Vet Private Limited and Indosol Pure Technologies Private Limited. The filing confirms the buyers are not related parties but does not disclose the sale price. The deal should bring a small one-time cash inflow and profit while trimming fixed assets, with no major impact on core operations.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Sajankumar Rameshwarlal Bajaj

Chairman of the Board, Managing Director, Executive Director

Rohan Parekh

Chief Financial Officer

Monica Tanwar

Company Secretary and Compliance Officer

Anil Champalal Jain

Joint Managing Director, Executive Director

Namrata Sajankumar Bajaj

Whole-Time Director